

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.


Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
DENVER, Sept. 16, 2019 — Medicine Man Technologies, Inc. (OTC: MDCL) (“Medicine Man Technologies” or the “Company”) announced a culmination of its roll-up strategy today that would solidify the Company as one of the largest vertically integrated cannabis […]
VANCOUVER, Washington, May 15, 2019 — After four years of monotherapy trials, data is now available to submit the long-anticipated pivotal trial for monotherapy to the FDA Trial will include 10 weeks of induction therapy […]
Discover Tomorrow’s Winning Stocks! Thank you for subscribing. Something went wrong. Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox. […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
